small molecule kinase inhibitor
Recently Published Documents


TOTAL DOCUMENTS

35
(FIVE YEARS 10)

H-INDEX

11
(FIVE YEARS 2)

Author(s):  
Cecilia C. Ayala-Aguilera ◽  
Teresa Valero ◽  
Álvaro Lorente-Macías ◽  
Daniel J. Baillache ◽  
Stephen Croke ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Marialuisa Moccia ◽  
Donglin Yang ◽  
Naga Rajiv Lakkaniga ◽  
Brendan Frett ◽  
Nicholas McConnell ◽  
...  

AbstractWe have recently described Pz-1, a benzimidazole-based type-2 RET and VEGFR2 inhibitor. Based on a kinome scan, here we show that Pz-1 is also a potent (IC50 < 1 nM) TRKA/B/C inhibitor. Pz-1 potently inhibited proliferation of human cancer cells carrying either RET- or TRKA oncoproteins (IC50 ~ 1 nM), with a negligible effect against RET- and TRKA-negative cells. By testing mutations, known to mediate resistance to other compounds, RET G810R/S, but not L730I/V, E732K, V738A and Y806N, showed some degree of resistance to Pz-1. In the case of TRKA, G595R and F589L, but not G667C, showed some degree of resistance. In xenograft models, orally administered Pz-1 almost completely inhibited RET- and TRKA-mutant tumours at 1–3 mg/kg/day but showed a reduced effect on RET/TRKA-negative cancer models. The activity, albeit reduced, on RET/TRKA-negative tumours may be justified by VEGFR2 inhibition. Tumours induced by NIH3T3 cells transfected by RET G810R and TRKA G595R featured resistance to Pz-1, demonstrating that RET or TRKA inhibition is critical for its anti-tumourigenic effect. In conclusion, Pz-1 represents a new powerful kinase inhibitor with distinct activity towards cancers induced by oncogenic RET and TRKA variants, including some mutants displaying resistance to other drugs.


2021 ◽  
Vol 14 (1) ◽  
pp. 46
Author(s):  
Koen G. A. M. Hussaarts ◽  
Leni van Doorn ◽  
Sander Bins ◽  
Dave Sprengers ◽  
Peter de Bruijn ◽  
...  

Hepatocellular carcinoma (HCC) recurrence after liver transplantation occurs in approximately 20% of patients. Most of these patients use immunosuppressant drugs. Meanwhile, patients with HCC recurrence are frequently treated with the small molecule kinase inhibitor (SMKI) sorafenib. However, sorafenib and many immunosuppressants are substrates of the same enzymatic pathways (e.g., CYP3A4), which may potentially result in altered SMKI or immunosuppressant plasma levels. Therefore, we investigated changes in drug exposure of both sorafenib and immunosuppressants over time in four patients with systemic immunosuppressant and sorafenib treatment after HCC recurrence. In this study, sorafenib exposure declined over time during combined treatment with immunosuppressants, while two patients also experienced declining tacrolimus plasma levels. Importantly, patients were unable to increase the sorafenib dose higher than 200 mg b.i.d. without experiencing significant toxicity. We recommend to treat patients using both sorafenib and immunosuppressants with a sorafenib starting dose of 200 mg b.i.d.


Theranostics ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. 1918-1936
Author(s):  
Ho Jin Lee ◽  
Phuong Chi Pham ◽  
Honglan Pei ◽  
Bumhee Lim ◽  
Seung Yeob Hyun ◽  
...  

2020 ◽  
Vol 24 ◽  
pp. 100838
Author(s):  
Markus Fischer ◽  
Meike Luck ◽  
Maximilian Werle ◽  
Holger A. Scheidt ◽  
Peter Müller

eLife ◽  
2020 ◽  
Vol 9 ◽  
Author(s):  
Sansana Sawasdikosol ◽  
Steven Burakoff

In this perspective review, the role Hematopoietic Progenitor Kinase 1 (HPK1) in tumor immunity will be reviewed, with special emphasis on how T cells are negatively-regulated at different junctures of cancer-immunity cycle by this regulatory kinase. The review will highlight the strengths and weaknesses of HPK1 as a candidate target for novel immuno-oncology (IO) drug development that is centered on the use of small molecule kinase inhibitor to modulate the immune response against cancer. Such a therapeutic approach, if proven successful, could supplement the cancer cell-centric standard of care therapies in order to fully meet the therapeutic needs of cancer patients.


NAR Cancer ◽  
2020 ◽  
Vol 2 (3) ◽  
Author(s):  
Eric H Kim ◽  
Dengfeng Cao ◽  
Nupam P Mahajan ◽  
Gerald L Andriole ◽  
Kiran Mahajan

Abstract The androgen receptor (AR) is a critical transcription factor in prostate cancer (PC) pathogenesis. Its activity in malignant cells is dependent on interactions with a diverse set of co-regulators. These interactions fluctuate depending on androgen availability. For example, the androgen depletion increases the dependence of castration-resistant PCs (CRPCs) on the ACK1 and HOXB13 cell survival pathways. Activated ACK1, an oncogenic tyrosine kinase, phosphorylates cytosolic and nuclear proteins, thereby avoiding the inhibitory growth consequences of androgen depletion. Notably, ACK1-mediated phosphorylation of histone H4, which leads to epigenetic upregulation of AR expression, has emerged as a critical mechanism of CRPC resistance to anti-androgens. This resistance can be targeted using the ACK1-selective small-molecule kinase inhibitor (R)-9b. CRPCs also deploy the bromodomain and extra-terminal domain protein BRD4 to epigenetically increase HOXB13 gene expression, which in turn activates the MYC target genes AURKA/AURKB. HOXB13 also facilitates ligand-independent recruitment of the AR splice variant AR-V7 to chromatin, compensating for the loss of the chromatin remodeling protein, CHD1, and restricting expression of the mitosis control gene HSPB8. These studies highlight the crosstalk between AR–ACK1 and AR–HOXB13 pathways as key mediators of CRPC recurrence.


2020 ◽  
Vol 21 (7) ◽  
pp. 2344 ◽  
Author(s):  
Jonas R. Knudsen ◽  
Agnete B. Madsen ◽  
Kaspar W. Persson ◽  
Carlos Henríquez-Olguín ◽  
Zhencheng Li ◽  
...  

The small molecule kinase inhibitor SBI-0206965 was originally described as a specific inhibitor of ULK1/2. More recently, it was reported to effectively inhibit AMPK and several studies now report its use as an AMPK inhibitor. Currently, we investigated the specificity of SBI-0206965 in incubated mouse skeletal muscle, measuring the effect on analog 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR)-stimulated AMPK-dependent glucose transport and insulin-stimulated AMPK-independent glucose uptake. Pre-treatment with 10 µM SBI-0206965 for 50 min potently suppressed AICAR-stimulated glucose transport in both the extensor digitorum longus (EDL) and soleus muscle. This was despite only a modest lowering of AICAR-stimulated AMPK activation measured as ACC2 Ser212, while ULK1/2 Ser555 phosphorylation was prevented. Insulin-stimulated glucose transport was also potently inhibited by SBI-0206965 in soleus. No major changes were observed on insulin-stimulated cell signaling. No general effect of SBI-0206965 on intracellular membrane morphology was observed by transmission electron microscopy. As insulin is known to neither activate AMPK nor require AMPK to stimulate glucose transport, and insulin inhibits ULK1/2 activity, these data strongly suggest that SBI-0206965 has a non-specific off-target inhibitory effect on muscle glucose transport. Thus, SBI-0206965 is not a specific inhibitor of the AMPK/ULK-signaling axis in skeletal muscle, and data generated with this inhibitor must be interpreted with caution.


2019 ◽  
Vol 36 (4) ◽  
pp. 896-915 ◽  
Author(s):  
Stacey A. Dacosta Byfield ◽  
Oluwakayode Adejoro ◽  
Ronda Copher ◽  
Debanjana Chatterjee ◽  
Prashant R. Joshi ◽  
...  

2019 ◽  
Vol 79 (8) ◽  
pp. 1996-2008 ◽  
Author(s):  
Yumi Yokoyama ◽  
Erin D. Lew ◽  
Ruth Seelige ◽  
Elizabeth A. Tindall ◽  
Colin Walsh ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document